File downloaded on 2026-11-08
Source URL: https://medicines.health.europa.eu/veterinary/en/600000052232

Ubrostar Red 100 mg / 280 mg / 100 mg Intramammary Suspension for cattle

Authorised

- Framycetin sulfate
- Benethamine penicillin
- Penethamate hydriodide

Product identification

Medicine name:
Ubrostar Red 100 mg / 280 mg / 100 mg Intramammary Suspension for cattle

Active substance:
Framycetin sulfate

Benethamine penicillin

Penethamate hydriodide

Target species:
Cattle

Route of administration:
Intramammary use

Product details

Active substance and strength:

Framycetin sulfate
100.00 milligram(s) / 1.00 Syringe

Benethamine penicillin
280.00 milligram(s) / 1.00 Syringe

Penethamate hydriodide
100.00 milligram(s) / 1.00 Syringe

Pharmaceutical form:
Intramammary suspension

Withdrawal period by route of administration:

Intramammary use:

- **Cattle**
  - Meat and offal. 10 day
  - Milk. 37 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QJ51RC25

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:
Valid

Authorised in:
Netherlands

Available in:
Netherlands

Package description:
Cardboard box or plastic container containing 120 single useintramammary syringes and 120 teat wipes (containing isopropanol 70%).Each 4.5 g syringe (cylinder with piston and cap, all made of low densitypolyethylene) contains 5 ml intramammary suspension.

Cardboard box or plastic container containing 60 single useintramammary syringes and 60 teat wipes (containing isopropanol 70%).Each 4.5 g syringe (cylinder with piston and cap, all made of low densitypolyethylene) contains 5 ml intramammary suspension.
Cardboard box or plastic container containing 20 single useintramammary syringes and 20 teat wipes (containing isopropanol 70%).Each 4.5 g syringe (cylinder with piston and cap, all made of low densitypolyethylene) contains 5 ml intramammary suspension.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
Boehringer Ingelheim Vetmedica GmbH

Marketing authorisation date:
8/11/1992

Manufacturing sites for batch release:
Lohmann Pharma Herstellung GmbH
Haupt Pharma Latina S.r.l.

Responsible authority:
Medicines Evaluation Board

Authorisation number:
REG NL 108011

Date of authorisation status change:
26/01/2022

Reference member state:
Ireland

Procedure number:
IE/V/0271/001

Concerned member states:
Belgium Bulgaria Czechia France Hungary Netherlands Poland Romania Slovakia Slovenia United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.

Summary of Product Characteristics